Browse KANK1

Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell projection, ruffle membrane Note=Colocalizes with KIF21A in membrane ruffles.; SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Nucleus. Note=Shuttles between the cytoplasm and nucleus.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus. Cell projection, ruffle membrane. Note=Shuttles between the cytoplasm and nucleus.
Domain PF12796 Ankyrin repeats (3 copies)
PF12075 KN motif
Function

Involved in the control of cytoskeleton formation by regulating actin polymerization. Inhibits actin fiber formation and cell migration. Inhibits RhoA activity; the function involves phosphorylation through PI3K/Akt signaling and may depend on the competetive interaction with 14-3-3 adapter proteins to sequester them from active complexes. Inhibits the formation of lamellipodia but not of filopodia; the function may depend on the competetive interaction with BAIAP2 to block its association with activated RAC1. Inhibits fibronectin-mediated cell spreading; the function is partially mediated by BAIAP2. Inhibits neurite outgrowth. Involved in the establishment and persistence of cell polarity during directed cell movement in wound healing. In the nucleus, is involved in beta-catenin-dependent activation of transcription. Potential tumor suppressor for renal cell carcinoma.

> Gene Ontology
 
Biological Process GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007015 actin filament organization
GO:0007162 negative regulation of cell adhesion
GO:0007163 establishment or maintenance of cell polarity
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0008286 insulin receptor signaling pathway
GO:0010639 negative regulation of organelle organization
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016055 Wnt signaling pathway
GO:0017038 protein import
GO:0022604 regulation of cell morphogenesis
GO:0030010 establishment of cell polarity
GO:0030031 cell projection assembly
GO:0030041 actin filament polymerization
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030336 negative regulation of cell migration
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0031333 negative regulation of protein complex assembly
GO:0031345 negative regulation of cell projection organization
GO:0031529 ruffle organization
GO:0031589 cell-substrate adhesion
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032535 regulation of cellular component size
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0032878 regulation of establishment or maintenance of cell polarity
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033157 regulation of intracellular protein transport
GO:0034446 substrate adhesion-dependent cell spreading
GO:0034504 protein localization to nucleus
GO:0035023 regulation of Rho protein signal transduction
GO:0035024 negative regulation of Rho protein signal transduction
GO:0035411 catenin import into nucleus
GO:0035412 regulation of catenin import into nucleus
GO:0035413 positive regulation of catenin import into nucleus
GO:0040013 negative regulation of locomotion
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0043254 regulation of protein complex assembly
GO:0043434 response to peptide hormone
GO:0044744 protein targeting to nucleus
GO:0045665 negative regulation of neuron differentiation
GO:0046578 regulation of Ras protein signal transduction
GO:0046580 negative regulation of Ras protein signal transduction
GO:0046626 regulation of insulin receptor signaling pathway
GO:0046627 negative regulation of insulin receptor signaling pathway
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0050768 negative regulation of neurogenesis
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051058 negative regulation of small GTPase mediated signal transduction
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051258 protein polymerization
GO:0051271 negative regulation of cellular component movement
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051961 negative regulation of nervous system development
GO:0060491 regulation of cell projection assembly
GO:0061041 regulation of wound healing
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072673 lamellipodium morphogenesis
GO:0090066 regulation of anatomical structure size
GO:0090303 positive regulation of wound healing
GO:0090316 positive regulation of intracellular protein transport
GO:0097178 ruffle assembly
GO:0097581 lamellipodium organization
GO:0198738 cell-cell signaling by wnt
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900025 negative regulation of substrate adhesion-dependent cell spreading
GO:1900027 regulation of ruffle assembly
GO:1900028 negative regulation of ruffle assembly
GO:1900076 regulation of cellular response to insulin stimulus
GO:1900077 negative regulation of cellular response to insulin stimulus
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902532 negative regulation of intracellular signal transduction
GO:1902593 single-organism nuclear import
GO:1902743 regulation of lamellipodium organization
GO:1902744 negative regulation of lamellipodium organization
GO:1903034 regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
GO:2000114 regulation of establishment of cell polarity
GO:2000146 negative regulation of cell motility
GO:2000392 regulation of lamellipodium morphogenesis
GO:2000393 negative regulation of lamellipodium morphogenesis
Molecular Function GO:0008013 beta-catenin binding
Cellular Component GO:0001726 ruffle
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032587 ruffle membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KANK1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KANK1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KANK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8050.0348
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1590.54
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5550.665
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2110.631
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2010.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2210.945
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0530.909
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1350.942
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2160.914
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.7150.588
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0330.985
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0350.802
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KANK1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KANK1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KANK1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KANK1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KANK1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KANK1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KANK1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKANK1
NameKN motif and ankyrin repeat domains 1
Aliases KANK; ANKRD15; ankyrin repeat domain 15; CPSQ2; ankyrin repeat domain-containing protein 15; kidney ankyrin ......
Chromosomal Location9p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KANK1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.